Revolution Medicines has begun shipping its experimental pancreatic cancer drug daraxonrasib through an expanded access program, marking a significant step toward potential FDA approval for one of medicine’s most challenging cancers. CEO Mark Goldsmith announced the company plans to submit daraxonrasib for regulatory approval in the coming months, based on promising trial results presented at the American Society of Clinical Oncology annual meeting.
Pancreatic Cancer Survival Rates by Stage at Diagnosis
Five-year relative survival rates, 2020-2022 data
Source: National Cancer Institute SEER Program, 2023 | Georgian Medical Journal News
Expanded Access Program Provides Hope for Late-Stage Patients
The expanded access program allows patients with advanced pancreatic cancer to receive daraxonrasib outside of clinical trials when no other treatment options remain. This compassionate use pathway typically precedes formal drug approval by several months, providing critical access for patients who cannot wait for the standard regulatory process.
Daraxonrasib targets KRAS G12C mutations, which occur in approximately 2% of pancreatic adenocarcinomas according to data from the National Cancer Institute. While this represents a small subset of patients, the targeted approach offers precision medicine benefits for those with the specific genetic alteration. Revolution Medicines has been developing the compound as part of a broader strategy to target previously “undruggable” cancer proteins.
The company’s decision to initiate expanded access suggests confidence in the drug’s safety profile and preliminary efficacy data. Such programs require FDA authorization and typically involve patients who have exhausted standard treatment options.
Clinical Trial Results Drive Regulatory Strategy
At ASCO 2026, Revolution Medicines presented updated results from its Phase 2 trial evaluating daraxonrasib in KRAS G12C-mutated solid tumors. The data showed measurable responses in pancreatic cancer patients, though specific response rates were not disclosed in the company announcement.
Pancreatic cancer remains one of the deadliest malignancies, with most patients diagnosed at advanced stages when surgery is no longer possible. Current standard treatments include chemotherapy combinations such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, but median survival rarely exceeds 12 months for metastatic disease according to recent clinical studies.
The company’s regulatory timeline suggests a potential approval decision could come within 12-18 months, assuming successful completion of the FDA submission process. Revolution Medicines joins several other companies pursuing innovative approaches to pancreatic cancer treatment, including immunotherapy combinations and novel targeted therapies.
Market Impact and Patient Access Considerations
The pharmaceutical industry has long struggled to develop effective treatments for pancreatic cancer, making any advancement significant for both patients and investors. Revolution Medicines’ stock price has reflected optimism around its KRAS-targeting platform, with daraxonrasib representing the lead compound in pancreatic indications.
If approved, daraxonrasib would compete in a market where treatment options remain limited and patient outcomes poor. The drug’s specific focus on KRAS G12C mutations means it would serve a targeted population, potentially commanding premium pricing similar to other precision oncology treatments. Access considerations will likely focus on genetic testing requirements and insurance coverage for the companion diagnostic.
Healthcare systems are increasingly emphasizing precision medicine approaches in cancer care, making targeted therapies like daraxonrasib strategically important despite their limited patient populations. The success of KRAS inhibitors in lung cancer has validated the target, potentially smoothing regulatory and payer acceptance in pancreatic indications.
Revolution Medicines has initiated expanded access for daraxonrasib while preparing FDA submission for pancreatic cancer treatment, targeting KRAS G12C mutations found in 2% of pancreatic adenocarcinomas.
— Mark Goldsmith, CEO, Revolution Medicines (ASCO 2026)
Key takeaways
- Daraxonrasib targets KRAS G12C mutations in approximately 2% of pancreatic cancer patients
- Expanded access program provides treatment option while FDA review proceeds
- Pancreatic cancer five-year survival rate remains at 12% across all stages
Frequently asked questions
What is expanded access for experimental drugs?
Expanded access allows patients with serious conditions to receive investigational drugs outside clinical trials when no approved alternatives exist. The FDA must authorize these programs based on safety data and potential benefit.
How common are KRAS G12C mutations in pancreatic cancer?
KRAS G12C mutations occur in approximately 2% of pancreatic adenocarcinomas, representing a small but significant subset of patients who could benefit from targeted therapy.
When might daraxonrasib receive FDA approval?
Revolution Medicines plans to submit for approval soon, with a potential decision expected within 12-18 months assuming successful regulatory review.
The progression of daraxonrasib through expanded access to potential approval represents broader trends in precision oncology and accelerated drug development pathways. Success in pancreatic cancer could validate Revolution Medicines’ KRAS-targeting platform across multiple tumor types, potentially transforming treatment options for patients with historically limited therapeutic choices.
Source: Revolution Medicines starts shipping experimental pancreatic cancer drug
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
